Pramlintide for post-bariatric hypoglycaemia.

Sheehan A, Goldfine A, Bajwa M, Wolfs D, Kozuka C, Piper J, Fowler K, Patti ME

Diabetes, obesity & metabolism9 Mar 2022Cited by 10 (Europe PMC)

PMID35137513PMCIDPMC9035096DOI10.1111/dom.14665PepBankPUB-35137513

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In participants with post-bariatric hypoglycemia, pramlintide did not change MMTT glucose versus baseline.
In plain wordsIn people with post-bariatric hypoglycemia, pramlintide did not change meal-test glucose compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeMMTT glucose
Study
n = 14
Comparator
baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
sequential increase to maximum 120 micrograms, mean 69 ± 32 mcg, three times daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
There were no differences in MMTT glucose, glucagon or insulin between baseline and post treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants with PBH following gastric bypass were recruited from outpatient clinics at the Joslin Diabetes Center, Boston, Massachusetts for an open-label study of pramlintide efficacy over 8 weeks.
Summary · context
A mixed-meal tolerance test (MMTT) was performed at baseline and after 8 weeks of subcutaneous pramlintide with a sequential dose increase to a maximum of 120 micrograms (mean 69 ± 32 mcg) three times daily.
Report a problemFND-3513751301
02HumanNon-randomized trialMechanism
In participants with post-bariatric hypoglycemia, pramlintide did not change MMTT insulin versus baseline.
In plain wordsIn people with post-bariatric hypoglycemia, pramlintide did not change meal-test insulin compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeMMTT insulin
Study
n = 14
Comparator
baseline
Analysis
Secondary
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
sequential increase to maximum 120 micrograms, mean 69 ± 32 mcg, three times daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
There were no differences in MMTT glucose, glucagon or insulin between baseline and post treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants with PBH following gastric bypass were recruited from outpatient clinics at the Joslin Diabetes Center, Boston, Massachusetts for an open-label study of pramlintide efficacy over 8 weeks.
Summary · context
A mixed-meal tolerance test (MMTT) was performed at baseline and after 8 weeks of subcutaneous pramlintide with a sequential dose increase to a maximum of 120 micrograms (mean 69 ± 32 mcg) three times daily.
Report a problemFND-3513751303
03HumanNon-randomized trialEfficacy outcome
In participants with post-bariatric hypoglycemia, pramlintide did not significantly change satiety scores versus baseline.
In plain wordsIn people with post-bariatric hypoglycemia, pramlintide did not significantly change fullness scores compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeSatiety score
Study
n = 14
Comparator
baseline
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
sequential increase to maximum 120 micrograms, mean 69 ± 32 mcg, three times daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
We observed no significant change in satiety or dumping scores.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants with PBH following gastric bypass were recruited from outpatient clinics at the Joslin Diabetes Center, Boston, Massachusetts for an open-label study of pramlintide efficacy over 8 weeks.
Summary · context
A mixed-meal tolerance test (MMTT) was performed at baseline and after 8 weeks of subcutaneous pramlintide with a sequential dose increase to a maximum of 120 micrograms (mean 69 ± 32 mcg) three times daily.
Report a problemFND-3513751304
04HumanNon-randomized trialEfficacy outcome
In participants with post-bariatric hypoglycemia, pramlintide did not significantly change dumping scores versus baseline.
In plain wordsIn people with post-bariatric hypoglycemia, pramlintide did not significantly change dumping scores compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeDumping score
Study
n = 14
Comparator
baseline
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
sequential increase to maximum 120 micrograms, mean 69 ± 32 mcg, three times daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
We observed no significant change in satiety or dumping scores.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants with PBH following gastric bypass were recruited from outpatient clinics at the Joslin Diabetes Center, Boston, Massachusetts for an open-label study of pramlintide efficacy over 8 weeks.
Summary · context
A mixed-meal tolerance test (MMTT) was performed at baseline and after 8 weeks of subcutaneous pramlintide with a sequential dose increase to a maximum of 120 micrograms (mean 69 ± 32 mcg) three times daily.
Report a problemFND-3513751305
05HumanNon-randomized trialEfficacy outcome
In participants with post-bariatric hypoglycemia, low sensor-glucose frequency did not change with pramlintide, despite substantial individual variability.
In plain wordsIn people with post-bariatric hypoglycemia, low-glucose frequency did not change from baseline with pramlintide, although individual responses varied.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeFrequency of low sensor glucose
Study
n = 14
Comparator
baseline
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
sequential increase to maximum 120 micrograms, mean 69 ± 32 mcg, three times daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
The overall frequency of low SG values did not change, although there was substantial inter-individual variability.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants with PBH following gastric bypass were recruited from outpatient clinics at the Joslin Diabetes Center, Boston, Massachusetts for an open-label study of pramlintide efficacy over 8 weeks.
Summary · context
A mixed-meal tolerance test (MMTT) was performed at baseline and after 8 weeks of subcutaneous pramlintide with a sequential dose increase to a maximum of 120 micrograms (mean 69 ± 32 mcg) three times daily.
Report a problemFND-3513751306
06HumanNon-randomized trialMechanism
In participants with post-bariatric hypoglycemia, pramlintide did not change MMTT glucagon versus baseline.
In plain wordsIn people with post-bariatric hypoglycemia, pramlintide did not change meal-test glucagon compared with baseline.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeMMTT glucagon
Study
n = 14
Comparator
baseline
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
sequential increase to maximum 120 micrograms, mean 69 ± 32 mcg, three times daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
There were no differences in MMTT glucose, glucagon or insulin between baseline and post treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants with PBH following gastric bypass were recruited from outpatient clinics at the Joslin Diabetes Center, Boston, Massachusetts for an open-label study of pramlintide efficacy over 8 weeks.
Summary · context
A mixed-meal tolerance test (MMTT) was performed at baseline and after 8 weeks of subcutaneous pramlintide with a sequential dose increase to a maximum of 120 micrograms (mean 69 ± 32 mcg) three times daily.
Report a problemFND-3513751302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01841359

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Joslin Diabetes Centern = 222 Feb 2010 to 8 Feb 2022

Hypoglycemia · Evidence of Previous Gastric Surgery

Trial page ClinicalTrials.govUpdated 29 Jun 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.